GSA Capital Partners LLP maintained its position in Harvard Bioscience, Inc. (NASDAQ:HBIO) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 230,019 shares of the medical instruments supplier’s stock at the end of the second quarter. GSA Capital Partners LLP owned 0.66% of Harvard Bioscience worth $587,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of HBIO. Ameriprise Financial Inc. purchased a new position in Harvard Bioscience during the second quarter worth approximately $752,000. Essex Investment Management Co. LLC raised its stake in Harvard Bioscience by 38.7% during the second quarter. Essex Investment Management Co. LLC now owns 429,460 shares of the medical instruments supplier’s stock worth $1,095,000 after purchasing an additional 119,878 shares during the period. Glacier Peak Capital LLC raised its stake in Harvard Bioscience by 9.8% during the second quarter. Glacier Peak Capital LLC now owns 1,316,993 shares of the medical instruments supplier’s stock worth $3,358,000 after purchasing an additional 117,418 shares during the period. Royce & Associates LP raised its stake in Harvard Bioscience by 2.9% during the first quarter. Royce & Associates LP now owns 1,557,600 shares of the medical instruments supplier’s stock worth $4,050,000 after purchasing an additional 44,000 shares during the period. Finally, Renaissance Technologies LLC raised its stake in Harvard Bioscience by 5.9% during the first quarter. Renaissance Technologies LLC now owns 560,500 shares of the medical instruments supplier’s stock worth $1,457,000 after purchasing an additional 31,300 shares during the period. 61.00% of the stock is currently owned by institutional investors.

WARNING: “GSA Capital Partners LLP Maintains Stake in Harvard Bioscience, Inc. (HBIO)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/10/09/gsa-capital-partners-llp-maintains-stake-in-harvard-bioscience-inc-hbio.html.

A number of equities analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Friday, July 14th. ValuEngine raised shares of Harvard Bioscience from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, TheStreet raised shares of Harvard Bioscience from a “d+” rating to a “c-” rating in a research note on Monday, July 31st. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $4.75.

Harvard Bioscience, Inc. (HBIO) opened at 3.75 on Monday. Harvard Bioscience, Inc. has a 52 week low of $2.25 and a 52 week high of $3.90. The stock’s market cap is $130.63 million. The stock has a 50 day moving average of $3.28 and a 200-day moving average of $2.75.

Harvard Bioscience (NASDAQ:HBIO) last posted its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.01 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.03 by ($0.02). The business had revenue of $25.21 million during the quarter, compared to the consensus estimate of $24.00 million. Harvard Bioscience had a positive return on equity of 1.45% and a negative net margin of 4.37%. Analysts forecast that Harvard Bioscience, Inc. will post $0.13 earnings per share for the current year.

About Harvard Bioscience

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

Institutional Ownership by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Stock Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related stocks with our FREE daily email newsletter.